Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shionogi To Submit NDA For Flu Drug Premivir In Japan

This article was originally published in PharmAsia News

Executive Summary

Shionogi announced the company is preparing for a NDA submission in Japan for anti-viral flu agent and neuraminidase inhibitor premivir within the year. The Osaka-based company said a domestic clinical trial of the drug has shown promising results and it is conducting a thorough data analysis and preparing application documents for a NDA submission. Shionogi obtained the exclusive rights to premivir in Japan from BioCryst Pharmaceuticals of the U.S, where the drug is under Phase II development. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts